Related Experiment Video

Updated: Jun 9, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected

Marina Matas1, Antònia Picornell, Carmen Cifuentes

  • 1Institut Universitari d'Investigacions en Ciències de la Salut (IUNICS) i Laboratori de Genètica, Departament de Biologia, Universitat de les Illes Balears, Campus de la UIB, Palma de Mallorca, Illes Balears, Spain.

Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
|August 25, 2010
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) coinfection accelerates liver fibrosis. Genetic variability in HCV, particularly genotype 3a, correlates with increased liver damage markers in coinfected patients.

Area of Science:

  • Hepatology and Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) is a primary cause of chronic liver disease globally.
  • HCV infection accelerates liver fibrosis in patients coinfected with human immunodeficiency virus-1 (HIV-1) via poorly understood mechanisms.
  • Limited data exists on the genetic variability of HCV and HIV in coinfection contexts.

Purpose of the Study:

  • To investigate the association between liver damage, patient characteristics, and HCV genetic variability in HCV-HIV coinfected individuals.
  • To explore factors influencing HCV disease progression in coinfected patients.

Main Methods:

  • Utilized statistical generalized linear models (GLM) for analysis.
  • Assessed fibrosis staging noninvasively using Forns, APRI, and FIB-4 indexes.
  • Estimated HCV genetic variability by sequencing the core region and constructing phylogenetic trees.

Main Results:

  • Identified a direct correlation between fibrosis biomarkers and the AST/ALT ratio.
  • Observed a correlation with specific demographic/epidemiological factors like MoftIDU (most likely injection drug use).
  • Found a significant association between fibrosis markers and Hepatitis C virus (HCV) genotype 3a clades.

Conclusions:

  • HCV-HIV coinfection presents complex interactions influencing liver disease progression.
  • HCV genetic variability, specifically genotype 3a, plays a role in the degree of liver fibrosis.
  • Noninvasive fibrosis markers, patient characteristics, and viral genetics are crucial for understanding disease severity.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...